Meet
Jing Peng

Senior Research Scientist

Jing Peng uses her expertise in Medicare and other public insurance programs to provide life sciences manufacturers, health plans, professional associations, and patient groups with data-driven analyses and advanced statistics support.

In recent projects, Jing has helped life sciences manufacturers analyze claims data in specific disease areas to identify coding and reimbursement barriers that limit access to medicines and to map patient journeys to help clients develop patient support programs tailored to mitigate access barriers affecting specific patient populations.

Before joining Avalere, Jing served as a data scientist at Cormac where she designed, developed, and implemented research methods and advanced data analytics techniques in support of the Centers for Medicare & Medicaid Services’ Post-Acute Care Quality Reporting Programs. She also served as a statistician with Integrity Management Services, applying her knowledge of Medicare and Medicaid policy, healthcare coding, and statistical analysis to identify potential waste, fraud, and abuse in the Medicare and Medicaid programs.

Jing holds an MS in statistics and a BS in economics from George Mason University, and a BA in international economics and trade from the Wuhan University of Technology. She is a member of the American Statistical Association.

Authored Content


Analysis of data in the CMS VRDC shows that MA-PD utilization has steadily increased in therapeutic areas likely to have large increases in plan liability under Part D redesign.

Avalere and the Amputee Coalition analyzed claims data to understand the prevalence of limb loss and limb difference and the implications for public policy.

Variation in mix of payer coverage across autoimmune diseases highlights the need for manufacturers to assess patient payer mix to support channels of access.

Among Medicare FFS beneficiaries with diagnoses that are indicative of obesity, total healthcare spending rises dramatically as BMI group increases.

Among Medicare Fee-for-Service (FFS) beneficiaries, potential rare disease patients' residences have a median distance of over 200 miles to a relevant clinical trial site.

Assessing barriers that impact patient access to obesity care and educating stakeholders on how to mitigate them can advance solutions toward improving care.

Avalere research was published online in the Journal of Clinical Oncology Clinical Cancer Informatics, showing a considerable drop in cancer screening, diagnosis, and treatment for Medicare beneficiaries as a result of the ongoing COVID-19 pandemic.

Avalere continues to find a significant drop in utilization of key physician-administered therapies in 2020 relative to 2019.